TGD001 Treatment in Thrombotic Microangiopathies

Summary

This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.

Timeline

Start

2026-05-31

Primary completion

2028-05-31

Completion

2028-08-30

Drugs

Indications